Hudson Bay Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hudson Bay Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$342K	–	1650
2025 Q2	$342K	Buy	+20,000	New	+$853K	﹤0.01%	1152
2017 Q1	–	Sell	-66,900	Closed	-$1.83M	–	902
2016 Q4	$1.83M	Sell	66,900 -124,000	-65%	-$4.98M	0.04%	367
2016 Q3	$11.7M	Buy	190,900 +168,400	+748%	+$5.09M	0.28%	63
2016 Q2	$429K	Buy	+22,500	New	+$417K	0.01%	309

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hudson Bay Capital Management's SRPT Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Sarepta Therapeutics (SRPT) stake by 73% in Q2 2026, buying an estimated $3.59M and bringing the position to 450,000 shares worth $8.09M. The position accounts for 0.02% of the portfolio, ranked #416.

Hudson Bay Capital Management first reported a position in SRPT in Q2 2016 and has held it in 28 quarters since. The position peaked at $33.1M in Q3 2016. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Hudson Bay Capital Management held 450,000 shares of Sarepta Therapeutics worth $8.09M as of Q2 2026.
Hudson Bay Capital Management bought 190,000 Sarepta Therapeutics shares in Q2 2026, an estimated $3.59M.
Sarepta Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q2 2026, its #416 holding.
Hudson Bay Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 28 quarters since.
Hudson Bay Capital Management's Sarepta Therapeutics position peaked at $33.1M in Q3 2016.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.